Artivion(AORT) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - For the full year of 2025, total adjusted constant currency revenue growth was 13% and Adjusted EBITDA growth was 26% year-over-year, resulting in positive free cash flow for the year [4][12] - Total adjusted revenues for Q4 2025 were $118.3 million, up 18.5% compared to Q4 2024, while adjusted EBITDA increased approximately 29% from $17.6 million to $22.7 million [12][13] - Adjusted EBITDA margin was 19.2% in Q4 2025, an improvement of approximately 110 basis points over the prior year [13] Business Line Data and Key Metrics Changes - Stent graft revenues grew 36% on a constant currency basis in Q4 2025 compared to the same period last year, driven by AMDS in the U.S. and strong international growth [5][16] - On-X revenues grew 24% year-over-year on a constant currency basis in Q4 2025, supported by global market share gains and new U.S. market opportunities [6][16] - Tissue processing revenue increased 6% year-over-year on a constant currency basis in Q4 2025, while BioGlue revenues were flat compared to the same period last year [7][16] Market Data and Key Metrics Changes - Revenues in Asia Pacific increased 32%, North America increased 18%, EMEA increased 17%, and Latin America increased 9% compared to Q4 2024 [17] - Gross margins were 63% in both 2025 and 2024, with the 2024 gross margin negatively impacted by an idle plant charge due to a cybersecurity incident [17] Company Strategy and Development Direction - The company aims to replicate its successful strategy by introducing additional stent graft products generating revenue in Europe to the U.S. and Japan, which is expected to expand the total addressable market [5] - Key growth drivers include the commercialization of AMDS in the U.S., leveraging new clinical data for On-X heart valves, and advancing the NEXUS PMA [28][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering sustainable double-digit revenue growth and driving EBITDA margin expansion, with expectations for constant currency growth between 10%-14% for 2026 [20][24] - The company anticipates challenges in the AMDS launch due to tougher year-over-year comparisons but remains optimistic about growth opportunities [22][41] Other Important Information - The company recorded a $2.3 million adjustment to revenue for estimated payback obligations due to Italian government legislation, which has been excluded from adjusted revenue [14][15] - Free cash flow for the full year was approximately $1 million, despite significant investments in business expansion [19] Q&A Session Summary Question: Impact of Italian clawback on growth - Management clarified that the Italian payback impacted the EMEA line and did not skew the growth rates of major product lines [32][34] Question: Sell-in versus sell-through for AMDS - Management indicated that while specific revenue details are not disclosed, implantations are growing well, and the first experiences for surgeons have been positive [36][41] Question: Market opportunity for NEXUS - Management described the NEXUS market as nascent, with a U.S. market opportunity of $150 million, and emphasized the unique technology's potential to gain market share [42][44] Question: Pricing strategy for AMDS and NEXUS - Management confirmed that the pricing levels for AMDS and NEXUS are seen as appropriate, with favorable reimbursement dynamics supporting demand [51] Question: CapEx plans for 2026 - Management indicated that the $50 million CapEx for 2026 is primarily for capacity expansion for On-X and internal IT investments [68]